Molecular biology and post-angioplasty restenosis

Atherosclerosis

Volumn 123, Issue 1-2, 1996, Pages 17-31

  Nikol, S ^a   Huehns, T Y ^a   Hofling B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE; CORONARY ARTERY DISEASE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATOR GENE; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0029901486     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05807-8     Document Type: Review

References (79)

1. Gruentzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.
2. Lange RA, Hillis LD. Immediate angioplasty for acute myocardial infarction. N Engl J Med 1993;328:726.
3. Lincoff MA, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Circulation 1994;90:2070.
4. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616.
5. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter P, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 1988;77:361.
6. Topol EJ. Caveats about elective coronary stenting. N Engl J Med 1994;331:539.
7. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part I). Drugs 1993;46:18.
8. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758.
9. Isner JM. Vascular remodeling. Honey, I think I shrunk the artery. Circulation 1994;89:2937.
10. Höfling B, Pölnitz AV, Backa D, Arnim TV, Lauterjung L, et al. Percutaneous removal of atheromatous plaques in peripheral arteries. Lancet 1988;1:384.
11. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426.
12. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988;82:1134.
13. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155.
14. Nabel EG, Yang Z, Liptay S, San H, Gordon D, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimai hyperplasia in vivo. J Clin Invest 1993;91:1822.
15. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science 1989;243:1564.
16. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, et al. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990;111:2149.
17. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739.
18. Nabel EG, Yang ZY, Plautz G, Forough R, Zhan X, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993;362:844.
19. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ Res 1993;73:589.
20. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res 1979;28:501.
21. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;63:515.
22. Chen JK, Hoshi H, McKeehan WL. Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci U S A 1987;84:5287.
23. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, et al. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 1992;90:1582.
24. Nikol S, Weir L, Sullivan A, Sharaf B, White CJ, et al. Persistently increased expression of the transforming growth factor-β1 gene in human vascular restenosis: analysis of 62 patients with one or more episodes of restenosis. Cardiovasc Path 1994;3:57.
25. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993;90:10759.
26. Nellen D, Affolter M, Basler K. Receptor serine/theoserine kinases implicated in the control of Drosophila body pattern by decapentaplegic. Cell 1994;78:225.
27. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 1993;204:356.
28. Roberts AB, Sporn MB. In: Sporn MB and Roberts AB, (eds.), Handbook of Experimental Pharmacology: Peptide Growth Factors and their Receptors, (Springer Verlag, Berlin) 1990;419.
29. Hearn JA, Donohue BC, Ba'albaki H, et al. Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736.
30. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439.
31. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995;91:2687.
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841.
33. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 1991;47:236.
34. Klagsbrun M. Regulators of angiogenesis: stimulators, inhibitors and extracellular matrix. J Cell Biochem 1991;47:199.
35. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. Hypertension 1993;21:894.
36. Kindy MS, Sonenshein GE. Regulation of oncogene expression in cultured aortic smooth muscle cells. Post-transcriptional control of c-myc mRNA. J Biol Chem 1986;261:12865.
37. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67.
38. Simons M, Morgan KG, Parker C, Collins E, Rosenberg RD. The proto-oncogene c-myb mediates an intracellular calcium rise during the late G1 phase of the cell cycle. J Biol Chem 1993;268:627.
39. Campan M, Desgranges C, Gadeau AP, Millet D, Belloc F. Cell cycle dependent gene expression in quiescent stimulated and asynchronously cycling arterial smooth muscle cells in culture. J Cell Physiol 1992;150:493.
40. Chang MW, Barr E, Lu MM, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260.
41. Marx J. How p53 suppresses cell growth. Science 1993;262:1644.
42. Speir E, Modali R, Huang ES, Leon MB, Shawl F, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391.
43. Bravo R, Frank R, Blundell PA, Macdonald BH. Cyclin/ PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987;326:515.
44. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993;91:1469.
45. Yu CC, Filipe MI. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J 1993;25:843.
46. Schroeder TE. Actin in dividing cells: contractile ring filaments bind heavy meromyosin. Proc Natl Acad Sci 1973;70:1688.
47. Grainger DJ, Hesketh TR, Metcalfe JC, Weissberg PL. A large accumulation of non-muscle myosin occurs at first entry into M phase in rat vascular smooth-muscle cells. Biochem J 1991;277:145.
48. Krumlauf R. Hox genes in vertebrate development. Cell 1994;78:191.
49. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gaχ, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem 1995;270:5457.
50. Chavrier P, Zerial M, Lemaire P, Almendral J, Bravo R, et al. A gene encoding a protein with zinc fingers is activated during G0/G1 transition in cultured cells. EMBO J 1988;7:29.
51. Sukhatme VP, Cao XM, Chang LC, Tsai MC, Stamenkovich D, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988;53:37.
52. Thompson JD, Macejak D, Couture L, Stinchcomb DT. Ribozymes in gene therapy. Nature Med 1995;1:277.
53. Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WR, et al. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994;93:644.
54. Salmons B, Günzburg WH. Targeting of retroviral vectors for gene therapy. Hum Gene Ther 1993;4:129.
55. Miller AD. Human gene therapy comes of age. Nature 1992;357:455.
56. Wilson JM, Grossman M, Raper SE, Baker JJ, Newton RS, et al. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 1992;3:179.
57. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993;261:209.
58. Höfling B, Huehns TY. Intravascular local drug delivery after restenosis. Eur Heart J 1995;16:437.
59. -[59] Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-β1. Nature 1990;346:371.
60. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 1992;339:213.
61. Kranzhöfer R, Schirmer J, Schömig A, von Hodenberg E, Pestel E, et al. Suppression of neointimal thickening and smooth muscle cell proliferation after arterial injury in the rat by inhibitors of Na-H exchange. Circ Res 1993;73:264.
62. Santoian ED, Schneider JE, Gravanis MB, Foegh M, Tarazona N, et al. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993;88:11.
63. Simons M, Rosenberg RD. Antisense non-muscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res 1992;70:835.
64. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93:820.
65. Abe J, Zhou W, Taguchi J, Takuwa N, Miki K, et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun 1994;198:16.
66. Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res 1995;76:176.
67. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474.
68. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994;90:944.
69. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian Y, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci USA 1995;92:4051.
70. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, D'Souza S, et al. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995;76:505.
71. Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 1992;90:2044.
72. Berk BC, Gordon JB, Alexander RW. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17:111B.
73. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987;61:296.
74. 2+ release in smooth muscle. Physiological role of inositol 1,4,5-trisphosphate in pharmacomechanical coupling. J Biol Chem 1989;264:17997.
75. Chang MW, Barr E, Seltzer J, Jiang Y, Nabel GJ, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518.
76. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137.
77. Gonschior P, Gerheuser F, Fleuhaus M, Huehns TY, Erdemci A, et al. Local photodynamic therapy to obviate tissue hyperplasia in an experimental restenosis model. Photobiol Photochem (in press).
78. Pickering JG, Bacha PA, Weir L, Jekanowski J, Nichols JC, et al. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. J Clin Invest 1993;91:724.
79. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781.